

Image

Docket Number: 037003-0280728

PATENT APPLICATION

Client Reference: 2000-30-0513A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

Mitchell REFF

Group Art Unit: 1644

Application No.: 09/982,849

Examiner: Ronald B. Schwadron

Filed: October 22, 2001

Confirmation No.: 7677

For: VARIANT IgG3 RITUXAN AND THERAPEUTIC USES THEREOF



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

Date: December 24, 2003
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Client Ref.

2000-30-0513A

Applicant: MITCHELL REFF

Appln. No.: 09/982,849

Filing Date: October 22, 2001

Examiner: R. Schwadron	Group Art Unit: 1644
------------------------	----------------------

Date: December 24, 2003 Page

1

of

1

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR	6,183,744 B1	02/2001	GOLDENBERG			
	BR	6,306,393 B1	10/2001	GOLDENBERG			
	CR						
	DR						
	ER						
	FR						

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
	GR								
	HR								
	IR								
	JR								
	KR								

	LR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
	MR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
	NR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.
	OR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
	PR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
	QR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp. 1696-1711.
	RR	Jensen, et al., "Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC C2B8, rituximab)," 1998, <i>Ann Hematol</i> , Vol. 77, pp 89-91.
	SR	
	TR	

Date Considered:

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.